Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. Co. has built its proprietary FUSION™ System discovery platform to develop a pipeline of covalent small molecule product candidates. Co.'s product candidate, BMF-219, is designed to be an orally bioavailable, selective irreversible covalent inhibitor of menin, a scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. We show 10 historical shares outstanding datapoints in our BMEA shares outstanding history coverage, used to compute BMEA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BMEA market cap history over the course of time is important for investors
interested in comparing BMEA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BMEA versus a peer is one thing; comparing
BMEA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BMEA can fluctuate over the course of history.
With this page we aim to empower investors researching BMEA by allowing them to research the BMEA market cap history. |
Free BMEA Email Alerts:
Video: The Importance of Market Cap
